SOUTH
SAN FRANCISCO, Calif., Aug. 30,
2022 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(NASDAQ: IDYA), a synthetic lethality focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics, announced its participation in investor
conferences and events in September
2022.
Citi's 17th Annual BioPharma Conference
September 7-8, 2022
Wells Fargo Healthcare Conference
September 7-9, 2022
Morgan Stanley 20th Annual Global Healthcare
Conference
September 12-14, 2022
Monday, September 12 at 4:15pm ET
Fireside chat with Yujiro Hata, Chief Executive Officer, IDEAYA
Biosciences, hosted by Ashwin Pai,
M.D. Managing Director
Baird 20th 2022 Global Healthcare Conference
September 13-14, 2022
Wednesday, September 14 at
9:05am ET
Corporate Presentation by Paul Stone, Chief Financial Officer, IDEAYA
Biosciences
Oppenheimer's Oncology Summit / University
of Texas MD Anderson Cancer Center
September 21, 2022
Cantor Oncology, Hematology & HemOnc Conference
September 28, 2022
Wednesday, September 28
Panel: "Novel Targets in Oncology: Risk vs.
Reward", with participation by Mike
White, Chief Scientific Officer, IDEAYA Biosciences
A live audio webcast of the event will be available, as
permitted by conference host, at the "Investors/News and
Events/Investor Calendar" section of the IDEAYA website at
https://ir.ideayabio.com/events. A replay of available
webcasts will be accessible for 30 days following the live
event.
About IDEAYA Biosciences
IDEAYA is a synthetic
lethality-focused precision medicine oncology company committed to
the discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's
approach integrates capabilities in identifying and validating
translational biomarkers with drug discovery to select patient
populations most likely to benefit from its targeted
therapies. IDEAYA is applying its early research and drug
discovery capabilities to synthetic lethality – which represents an
emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains
forward-looking statements, including, but not limited to,
statements related to participation in and/or presentation at
certain investor relations events. IDEAYA undertakes no obligation
to update or revise any forward-looking statements. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to the business of IDEAYA in
general, see IDEAYA's Quarterly Report on Form 10-Q filed on
August 15, 2022 and any current and
periodic reports filed with the U.S. Securities and Exchange
Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-investor-conferences-in-september-2022-301614751.html
SOURCE IDEAYA Biosciences, Inc.